Beijing Aosaikang Pharmaceutical's subsidiary signs ASKG712 project authorization license agreement.

Beijing Aosaikang Pharmaceutical (002755.SZ) announced that its controlling subsidiary, AskGene Pharma, Inc. (referred to as "AskGene Pharma"), has reached a licensing agreement with Visara, Inc. (referred to as "Visara"), whereby Visara will be granted the rights to AskGene Pharma's independently developed innovative drug ASKG712 in the licensed territory. ASKG712 is an independently developed innovative drug by AskGene Pharma with proprietary intellectual property rights, targeting both VEGF and ANG-2. By blocking the VEGF/VEGFR signaling pathway to control neovascular formation, it can effectively inhibit ANG-2 signaling to improve vascular stability and reduce retinal inflammation. It is currently in phase IIa clinical trials in China for the treatment of macular diseases. Phase I dosing escalation and expansion results have shown that ASKG712 has good safety and efficacy. Preclinical data also indicates that compared to current treatments, ASKG712 has stronger binding activity to VEGF and ANG-2, which may improve efficacy, lengthen dosing intervals, reduce frequent ocular injections, and improve patient compliance. This licensing agreement is beneficial for the research and commercialization process of the ASKG712 project in the licensed territory, allowing the company to further focus on innovative drug research in areas such as digestion, oncology, anti-infection, and chronic diseases, aligning with the company's overall strategic direction. It is expected that the implementation of the agreement will have a positive impact on the company's future performance.